Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:87 Suppl 1:22-31.
doi: 10.1159/000368142. Epub 2014 Nov 22.

Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update

Masatoshi Kudo  1 , Osamu Matsui, Namiki Izumi, Masumi Kadoya, Takuji Okusaka, Shiro Miyayama, Koichiro Yamakado, Kaoru Tsuchiya, Kazuomi Ueshima, Atsushi Hiraoka, Masafumi Ikeda, Sadahisa Ogasawara, Tatsuya Yamashita, Tetsuya Minami; Liver Cancer Study Group of Japan
Affiliations
Review

Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update

Masatoshi Kudo et al. Oncology. 2014.

Erratum in

  • Oncology. 2015;89 Suppl 2():71-2

Abstract

In the 2010 version of the Japan Society of Hepatology (JSH) consensus-based treatment algorithm for the management of hepatocellular carcinoma (HCC), transarterial chemoembolization (TACE) failure/refractoriness was defined assuming the use of superselective lipiodol TACE, which has been widely used worldwide and particularly in Japan, and areas with lipiodol deposition were considered to be necrotic. However, this concept is not well accepted internationally. Furthermore, following the approval of microspheres, an embolic material that does not use lipiodol, in February 2014 in Japan, the phrase 'lipiodol deposition' needed to be changed to 'necrotic lesion or viable lesion'. Accordingly, the respective section in the JSH guidelines was revised to define TACE failure as an insufficient response after ≥2 consecutive TACE procedures that is evident on response evaluation computed tomography or magnetic resonance imaging after 1-3 months, even after chemotherapeutic agents have been changed and/or the feeding artery has been reanalyzed. In addition, the appearance of a higher number of lesions in the liver than that recorded at the previous TACE procedure (other than the nodule being treated) was added to the definition of TACE failure/refractoriness. Following the discussion of other issues concerning the continuous elevation of tumor markers, vascular invasion, and extrahepatic spread, descriptions similar to those in the previous version were approved. The revision of these TACE failure definitions was approved by over 85% of HCC experts.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms